Abstract
The serum concentrations of osteocalcin (bone Gla protein) were followed by continuous blood sampling for 24 h in 9 healthy young women before and during treatment with oestrogen/progestogen combinations for oral contraception. There were marked fluctuations during the 24 h sampling period, values ranging from 0.5 to 10.0 ng/ml. Values displayed an apparent circadian rhythm. Daytime values were on average lower than nocturnal concentrations. During treatment with oral contraceptives there was a significant decrease in osteocalcin levels but fluctuations during the 24 h sampling period were still observed. Almost all individual values obtained at 30 min intervals were lower during treatment. For the whole group the mean osteocalcin concentration decreased by 1.4 ng/ml (p<0.01) during treatment. In postmenopausal women high serum levels of osteocalcin are supposed to reflect increased bone turnover secondary to enhanced bone resorption. Oestrogens are known to reduce osteocalcin levels and may reduce bone resorption. In healthy young women alternative mechanisms should be considered but the reduced osteocalcin serum levels in this short-term study indicate that oral contraceptive use may influence bone metabolism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lian JB, Gundberg CM. Osteocalcin. Clin Orthop 1988; 226:267–91.
Pødenphant J, Christiansen C, Catherwood BD, Deftos LJ. Serum bone Gla protein variations during oestrogen and calcium prophylaxis of postmenopausal women. Calcif Tissue Int 1984; 36:536–40.
Stock JL, Coderre JA, Malette LE. Effects of a short course of oestrogen on mineral metabolism in postmenopausal women. J Clin Endocrinol Metab 1985; 61:595–600.
Ismail F, Epstein S, Pacifici R, Droke D, Thomas SB, Avioli LV. Serum bone Gla protein and other markers of bone mineral metabolism in postmenopausal osteoporosis. Calcif Tissue Int 1986; 39:230–3.
Ismail F, Epstein S, Fallon MD, Thomas SB, Reinardt TA. Serum bone Gla protein and the vitamin D endocrine system in the oophorectomized rat. Endocrinology 1988; 122:624–30.
Yasumura S, Alora JF, Gundberg CM et al. Serum osteocalcin and total body calcium in normal pre- and postmenopausal women and postmenopausal osteoporotic patients. J Clin Endocrinol Metab 1987; 64:681–5.
Christiansen C, Riis BJ, Nilas L, Rødbro P, Deftos L. Uncoupling of bone formation and resorption by combined oestrogen and progestogen therapy in postmenopausal osteoporosis. Lancet 1985; 2:800–1.
Riis BJ, Johansen J, Christiansen C. Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women. Maturitas 1988; 10:51–8.
Gundberg CM, Markowitz ME, Mizruchi M, Rosen JF. Osteocalcin in human serum: a circadian rhythm. J Clin Endocrinol Metab 1985; 60:736–9.
Kowarski A, Thompson RG, Migeon CJ, Blizzard RM. Determination of integrated plasma concentrations and true secretion rates of human growth hormone. J Clin Endocrinol Metab 1971; 31:356–60.
Garcia-Carrasco M, Gruson M, de Vernejoul C, Denne MA, Mivaret L. Osteocalcin and bone morphometric parameters in adults without bone disease. Calcif Tissue Int 1988; 52:13–17.
Civitelli R, Agnusdei D, Nardi P, Zacchei F, Aviolo LV, Gennari C. Effects of one-year treatment with oestrogens on bone mass, intestinal calcium absorption and 25-hydroxy-vitamin D-1α-hydroxylase reserve in postmenopausal osteoporosis. Calcif Tissue Int 1988; 42:77–86.
Johansen JS, Riis BJ, Delmas PD, Christiansen C. Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. Eur J Clin Invest 1988; 18:191–5.
Delmas PD, Chatelain P, Malaval L, Bonne G. Serum bone Gla-protein in growth hormone deficient children. J Bone Miner Res 1986; 1:333–8.
Sidenius Johansen J, Giwercman A, Hartwell D et al. Serum bone Gla-protein as a marker of bone growth in children and adolescents: correlation with age, height, serum insulin-like growth factor I, and serum testosterone. J Clin Endocrinol Metab 1988; 67:273–8.
Dawson-Hughes B, Stern D, Goldman J, Reichlin S. Regulation of growth hormone and somatomedin-C secretion in post-menopausal women: effect of physiological estrogen replacement. J Clin Endocrinol Metab 1986; 63:424–32.
Fröhlander N, von Schoultz B. Growth hormone and somatomedin-C during postmenopausal replacement therapy with oestrogen alone and in combination with an antioestrogen. Maturitas 1988; 9:297–302.
Karlsson R, Eden S, von Schoultz B. Altered growth hormone secretion during oral contraception. Gynecol Obstet Invest 1990; 30:234–8.
Lindsay R, Tohme J, Kanders B. The effects of oral contraceptive use on vertebral bone mass in pre- and postmenopausal women. Contraception 1986; 34:333–40.
Lloyd T, Buchanan JR, Ursino GR, Mayers C, Woodward G, Halbert DR. Long-term oral contraceptive use does not affect trabecular bone density. Am J Obstet Gynecol 1989; 160:402–4.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Karlsson, R., Eden, S. & von Schoultz, B. Oral contraception affects osteocalcin serum profiles in young women. Osteoporosis Int 2, 118–121 (1992). https://doi.org/10.1007/BF01623817
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01623817